The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Association of BRCA1/2defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes
Open accessAbstract
Introduction: Homologous recombination (HR) DNA repair is of clinical relevance in breast cancer. Three DNA-based homologous recombination deficiency (HRD) scores (HRD-loss of heterozygosity score (LOH), HRD-telomeric allelic imbalance score (TAI), and HRD-large-scale state transition score (LST)) have been developed that are highly correlated with defects in BRCA1/2, and are associated with response to platinum therapy in triple negative breast and ovarian cancer. This study examines the frequency of BRCA1/2 defects among different breast cancer subtypes, and the ability of the HRD scores to identify breast tumors with defects in the homologous recombination DNA repair pathway. Methods: 215 breast tumors representing all ER/HER2 subtypes were obtained from commercial vendors. Next-generation sequencing based assays were used to generate genome wide SNP profiles, BRCA1/2 mutation screening, and BRCA1 promoter methylation data. Results: BRCA1/2 deleterious mutations were observed in all breast cancer subtypes. BRCA1 promoter methylation was observed almost exclusively in triple negative breast cancer. BRCA1/2 deficient tumors were identified with BRCA1/2 mutations, or BRCA1 promoter methylation, and loss of the second allele of the affected gene. All three HRD scores were highly associated with BRCA1/2 deficiency (HRD-LOH: P = 1.3 × 10-17; HRD-TAI: P = 1.5 × 10-19; HRD-LST: P = 3.5 × 10-18). A combined score (HRD-mean) was calculated using the arithmetic mean of the three scores. In multivariable analyses the HRD-mean score captured significant BRCA1/2 deficiency information not captured by the three individual scores, or by clinical variables (P values for HRD-Mean adjusted for HRD-LOH: P = 1.4 × 10-8; HRD-TAI: P = 2.9 × 10-7; HRD-LST: P = 2.8 × 10-8; clinical variables: P = 1.2 × 10-16). Conclusions: The HRD scores showed strong correlation with BRCA1/2 deficiency regardless of breast cancer subtype. The frequency of elevated scores suggests that a significant proportion of all breast tumor subtypes may carry defects in the homologous recombination DNA repair pathway. The HRD scores can be combined to produce a more robust predictor of HRD. The combination of a robust score, and the FFPE compatible assay described in this study, may facilitate use of agents targeting homologous recombination DNA repair in the clinical setting.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900212 · Cited by 3,634
Germline BRCA1 Mutations and a Basal Epithelial Phenotype in Breast Cancer
Foulkes, W. D. (2003) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/djg050 · Cited by 970
Abkevich, V, Timms, K. M., Hennessy, B. T., Potter, J., Carey, M. S., Meyer, L. A., Smith-McCune, K., Broaddus, R., Lu, K. H., Chen, J., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.451 · Cited by 815
Self-citationRe: Germline BRCA1 Mutations and a Basal Epithelial Phenotype in Breast Cancer
van der Groep, P., Bouter, A., van der Zanden, R., Menko, F. H., Buerger, H., Verheijen, R. H. M., van der Wall, E., & van Diest, P. J. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh114 · Cited by 798
Popova, T., Manié, E., Rieunier, G., Caux-Moncoutier, V., Tirapo, C., Dubois, T., Delattre, O., Sigal-Zafrani, B., Bollet, M., Longy, M., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-1470 · Cited by 665
Telomeric Allelic Imbalance Indicates Defective DNA Repair and Sensitivity to DNA-Damaging Agents
Birkbak, N. J., Wang, Z. C., Kim, J.-Y., Eklund, A. C., Li, Q., Tian, R., Bowman-Colin, C., Li, Y., Greene-Colozzi, A., Iglehart, J. D., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0206 · Cited by 661
Atchley, D. P., Albarracin, C. T., Lopez, A., Valero, V., Amos, C. I., Gonzalez-Angulo, A. M., Hortobagyi, G. N., & Arun, B. K. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.6231 · Cited by 604
Gonzalez-Angulo, A. M., Timms, K. M., Liu, S., Chen, H., Litton, J. K., Potter, J., Lanchbury, J. S., Stemke-Hale, K., Hennessy, B. T., Arun, B. K., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2560 · Cited by 573
Self-citationByrski, T., Gronwald, J., Huzarski, T., Grzybowska, E., Budryk, M., Stawicka, M., Mierzwa, T., Szwiec, M., Wiśniowski, R., Siolek, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.7019 · Cited by 516
A suggested nomenclature for designating mutations
Beaudet, A. L., & Tsui, L.-C. (1993) · Human Mutation · doi:10.1002/humu.1380020402 · Cited by 308
Cited by
Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Abraham, J., Aft, R., Agnese, D., Allison, K. H., Blair, S. L., Burstein, H. J., Dang, C., Elias, A. D., et al. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.0016 · Cited by 1,584
Lehmann, B. D., Jovanović, B., Chen, X., Estrada, M. V., Johnson, K. N., Shyr, Y., Moses, H. L., Sanders, M. E., & Pietenpol, J. A. (2016) · PLOS ONE · doi:10.1371/journal.pone.0157368 · Cited by 1,426
Lord, C. J., & Ashworth, A. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2015.21 · Cited by 1,257
Telli, M. L., Timms, K. M., Reid, J., Hennessy, B., Mills, G. B., Jensen, K. C., Szallasi, Z., Barry, W. T., Winer, E. P., Tung, N. M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2477 · Cited by 1,136
Self-citationJiang, Y.-Z., Ma, D., Suo, C., Shi, J., Xue, M., Hu, X., Xiao, Y., Yu, K.-D., Liu, Y.-R., Yu, Y., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.02.001 · Cited by 1,062
Metadata
- Authors
- Timms, K. M., Abkevich, V., Hughes, E., Neff, C., Reid, J., Morris, B., Kalva, S., Potter, J., Tran, T. V., Chen, J., Iliev, D., Sangale, Z., Tikishvili, E., Perry, M., Zharkikh, A., Gutin, A., & Lanchbury, J. S.
- Venue
- Breast Cancer Research
- Published
- 2014-12-05
- Volume
- 16
- Issue
- 6
- Pages
- 475-475
- ISSN
- 1465-5411 (ISSN-L)
- 1465-542X
- OpenAlex
- W2109772731
- Cited by
- 419
- References
- 15
- FWCI
- 12.88
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Association of BRCA1/2defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes. https://app.cochat.ai/papers/10.1186/s13058-014-0475-x
- The paper
- Timms, K. M., Abkevich, V., Hughes, E., Neff, C., Reid, J., Morris, B., Kalva, S., Potter, J., Tran, T. V., Chen, J., Iliev, D., Sangale, Z., Tikishvili, E., Perry, M., Zharkikh, A., Gutin, A., & Lanchbury, J. S. (2014). Association of BRCA1/2defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes. Breast Cancer Research. https://doi.org/10.1186/s13058-014-0475-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.